Overall hemostatic potential | |
---|---|
Synonyms | Overall hemostasis potential; Overall haemostasis potential; Overall haemostatic potential; OHP |
Test of | Coagulation, hypercoagulability, hypocoagulability, hemostasis, fibrinolysis |
The overall hemostatic potential (OHP) test is a global coagulation assay which can be used to measure coagulation. [1] [2] [3] [4] The OHP assay measures total fibrin generation in the presence of thrombin or tissue factor and tissue plasminogen activator (t-PA). [2] [1] [3] [4] It generates a fibrin time curve through the use of optical density measurement. [1] This curve represents the balance between fibrin formation induced by thrombin or tissue factor and fibrinolysis induced by t-PA. [1] The assay provides three parameters: overall coagulation potential (OCP), overall hemostatic potential (OHP), and overall fibrinolytic potential (OFP). [2] [1] [4] OHP is the main parameter, while OCP and OFP are supplementary parameters to assess coagulation and fibrinolysis. [3] One further parameter, clot lysis time (CLT), can also be determined. [3] The OHP assay measures the integrated effect of procoagulant, anticoagulant, and fibrinolytic factors. [1]
The OHP is a technically simple [1] [3] but relatively labor-intensive assay. [2] As of 2010, it had been implemented in several laboratories, but was not available commercially. [3] The assay is novel in terms of its combined evaluation of both fibrin generation and fibrinolysis. [1] The test is potentially useful in the evaluation of hypercoagulability, hypocoagulability, and fibrinolytic abnormalities. [1] [2] [3] It is able to detect hypercoagulability associated with pregnancy and estrogen/ progestogen hormone therapy. [3] [4] The test has also been used to study coagulation in feminizing hormone therapy in transgender women. [5] However, more studies are needed to validate the test as a biomarker of thrombosis and other abnormalities of coagulation. [2] [3] [4]
The original OHP assay was developed in Sweden by Blombäck and colleagues and was first described in 1999. [1] [6] [7] It used thrombin to trigger coagulation. [1] Since then, a modified version has been developed which can use either thrombin or tissue factor to trigger coagulation. [1] [3] [8] [9]
Overall hemostatic potential | |
---|---|
Synonyms | Overall hemostasis potential; Overall haemostasis potential; Overall haemostatic potential; OHP |
Test of | Coagulation, hypercoagulability, hypocoagulability, hemostasis, fibrinolysis |
The overall hemostatic potential (OHP) test is a global coagulation assay which can be used to measure coagulation. [1] [2] [3] [4] The OHP assay measures total fibrin generation in the presence of thrombin or tissue factor and tissue plasminogen activator (t-PA). [2] [1] [3] [4] It generates a fibrin time curve through the use of optical density measurement. [1] This curve represents the balance between fibrin formation induced by thrombin or tissue factor and fibrinolysis induced by t-PA. [1] The assay provides three parameters: overall coagulation potential (OCP), overall hemostatic potential (OHP), and overall fibrinolytic potential (OFP). [2] [1] [4] OHP is the main parameter, while OCP and OFP are supplementary parameters to assess coagulation and fibrinolysis. [3] One further parameter, clot lysis time (CLT), can also be determined. [3] The OHP assay measures the integrated effect of procoagulant, anticoagulant, and fibrinolytic factors. [1]
The OHP is a technically simple [1] [3] but relatively labor-intensive assay. [2] As of 2010, it had been implemented in several laboratories, but was not available commercially. [3] The assay is novel in terms of its combined evaluation of both fibrin generation and fibrinolysis. [1] The test is potentially useful in the evaluation of hypercoagulability, hypocoagulability, and fibrinolytic abnormalities. [1] [2] [3] It is able to detect hypercoagulability associated with pregnancy and estrogen/ progestogen hormone therapy. [3] [4] The test has also been used to study coagulation in feminizing hormone therapy in transgender women. [5] However, more studies are needed to validate the test as a biomarker of thrombosis and other abnormalities of coagulation. [2] [3] [4]
The original OHP assay was developed in Sweden by Blombäck and colleagues and was first described in 1999. [1] [6] [7] It used thrombin to trigger coagulation. [1] Since then, a modified version has been developed which can use either thrombin or tissue factor to trigger coagulation. [1] [3] [8] [9]